BML, Inc. provides contract clinical testing and related services in Japan. The company offers routine laboratory testing, such as biochemical and hematologic examination; special laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispensing. It also provides contract clinical testing, including endocrine, plasma protein, biochemical, viral, immunoserological, hematological, cellular immunity, bacteriological, and histopathological, pathological, and cytological tests; specimen receiving service; and medical information system services, which include electronic medical charts for clinics without beds. In addition, the company is involved in manufacturing and supply services for medical equipment and supplies; real estate leasing and insurance agency business; providing food hygiene inspection and food consulting services; and dispensing pharmacy services. The company was incorporated in 1955 and is headquartered in Tokyo, Japan.
Visit company website
5 years, 5 months ago
BML, Inc is currently in a long term uptrend where the price is trading 11.2% above its 200 day moving average.
From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.2.
BML, Inc's total revenue rose by 24.3% to $38B since the same quarter in the previous year.
Its net income has increased by 195.0% to $5B since the same quarter in the previous year.
Based on the above factors, BML, Inc gets an overall score of 4/5.